FDA Milestone: 75th Biosimilar Medication Is Approved!
U.S. Food and Drug Administration (FDA) shared on LinkedIn:
”Exciting Announcement!
The FDA has reached another milestone with the approval of its 75th biosimilar medication!
This achievement represents a major step forward in ensuring more patients have access to critical, life-saving treatments without compromising on quality or safety.
Learn more about biosimilars”
According to the FDA, a biosimilar is a biological product that closely resembles an already FDA-approved reference product and shows no clinically significant differences in safety or effectiveness.
Biosimilars are approved for use across a wide range of diseases, from Crohn’s disease to HER2-positive breast cancer.
For example, Zarxio can serve as an alternative to Neupogen (filgrastim), while the newly approved Avsola is intended to replace Remicade (infliximab) for various autoimmune conditions.
One key advantage of these drugs is that they maintain high standards of safety, efficacy, and quality, while also providing more cost-effective treatment options.
Thus, biosimilar products approved by FDA must also meet requirements mentioned in Biologics Price Competition and Innovation Act.
More on the latest FDA Approvals featured in Hemostasis Today.
-
Oct 6, 2025, 04:10EAHAD PT Committee Chair Ruth Elise Is Contributing to The Discussion On Joint Health and Mobility At EHC 2025
-
Oct 6, 2025, 03:44Caitlin Raymond: When We Talk About Plasma Exchange, Most Discussions Stop At What We’re Removing, But That’s Only Half The Story
-
Oct 6, 2025, 03:20Gianluigi Pasta On Cutting-Edge Cartilage Engineering for Bleeding Disorders Community at EHC 2025
-
Oct 5, 2025, 12:02Joseph Raffaele: Everyone Asks Me About Testosterone. Few Ask About DHEA
-
Oct 5, 2025, 11:58Dr Shamee Shastry and Team Establish New Insights on Critical Antibody Titers
-
Oct 6, 2025, 03:48New Insights On Pre-Existing AAV5 Abs in Haemophilia B Gene Therapy
-
Oct 6, 2025, 03:40Emmanuel J Favaloro and Leonardo Pasalic's Commentary On Acquired von Willebrand Syndrome in Children
-
Oct 5, 2025, 16:40Dr. Kalpana Gupta Shekhawat Insights About Leucovorin and how it Works on the Brain
-
Oct 5, 2025, 12:43Nita Radhakrishnan and Colleagues on Tertiary Prophylaxis with Extended Half-life Factor in LMIC Settings
-
Oct 5, 2025, 12:15Laura Avila and Colleagues on Childhood DVT: Upper Extremity (UE) Post-thrombotic Syndrome (PTS)
-
Oct 3, 2025, 15:31Anirban Sen Gupta and Andrew Shoffstall Collaboration on Bioinspired Synthetic Platelet Systems for Brain Injury Treatment
-
Oct 3, 2025, 15:07Shai Shen-Orr: Excited to Share that The Human Immunome Project (HIP) Has Launched Its Scientific Partner Network
-
Oct 2, 2025, 04:59Caterina Casari - Prizes for Innovators 2025 Winner!
-
Oct 2, 2025, 04:572025 Innovators Award: Ile de France Région Recognizes 3 Researchers Who Have Committed Themselves to The Innovation
-
Oct 1, 2025, 15:59Anirban Sen Gupta: Thrilled to share a great collaboration story in Nature Portfolio
-
Oct 6, 2025, 03:57Mattia Galli - Nominated Among The Top 200 of 200,000 Leading Researchers Worldwide for The 2025 USERN Prize!
-
Oct 6, 2025, 03:46Marilena Vrana: I Want to Thank Grifols Deutschland for The Opportunity to Visit Their Premises and Biotest AG Manufacturing Facility in Dreieich
-
Oct 6, 2025, 03:43Maha Othman: Real-World Learning Is Essential in Preparing Our Future Nurses!
-
Oct 6, 2025, 03:10Moath Albliwi to Present 4 Major Posters at 67th ASH Annual Meeting 2025
-
Oct 5, 2025, 12:29Miguel Crato: I Feel I Must Always Be Strong, But That Wears Me Down